Targeted nanomedicines for the treatment of neurological diseases
Dr. Óscar A. Marcos Contreras
Assistant Professor. Lewis Katz School of Medicine, Temple University (USA)
Online via ZOOM
About
Neuroinflammation and a disrupted blood-brain barrier (BBB) are key pathological features of acute neurovascular diseases. A targeted nanocarrier platform addresses these challenges via VCAM-1-directed delivery to the inflamed BBB, enabling precise therapeutic intervention.
A complementary strategy targets ICAM-1, providing an innovative mechanism for in vivo cell-based delivery to the inflamed brain through white blood cells.
Bio
- Associate Professor of Pathology and Laboratory Medicine at Lewis Katz School of Medicine, with doctoral (PhD) and professional (PharmD) training from University of Alcalá.
- Research interests include stroke, neuroinflammatory and chronic neurological diseases, blood-brain barrier (BBB), gene therapy, nanomedicine and hematology.
- Principal Investigator on major grants: NIH for targeted nanomedicine to improve BBB function in acute ischemic stroke; American Heart Association Career Development Award for cell-specific drug delivery to the inflamed brain, etc.
- Numerous patents and patent applications on targeted delivery systems, therapeutic lipid nanoparticles, and methods for treating neurological conditions.
Hosted by María José Alonso. Nanomedicine and Drug Delivery group, CiMUS.
Certificates of attendance will be provided upon request at cimus.xestion [at] usc.es (cimus[dot]xestion[at]usc[dot]es). Please do not forget to enter your full name and surname when registering online for the lecture.